26 October 2021 - The Medicines and Healthcare products Regulatory Agency has licensed Gedeon Richter UK’s Ryeqo (relugolix combination therapy) for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

The decision to license Ryeqo is based on results from the Phase 3 LIBERTY programme, consisting of two 24-week, double-blind, randomised and multinational clinical trials.

Read Pharma Times article